-202506-1749019964.jpg&w=3840&q=100)
Weight Loss: 7 low-calorie snacks that can help you shed those extra kilos
Veggie Upma is a healthy dish, which is light and loaded with dietary fibre and essential vitamins.
Masala oats are high in fibre, making it beneficial for your gut and weight loss.
Sprouted moong salad is an easy snack, which is rich in nutrients and promotes weight loss.
Carrot/Cucumber Sticks and Hummus provide you with healthy calories and increase fibre intake.
Idlis served with coconut chutney is a healthy South-Indian delicacy perfect for weight loss.
Buttermilk and Nuts are blend of fermented drink, healthy fats, and protein.
Roasted Chana supplies a nice amount of protein and can curb hunger pangs for a while.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
an hour ago
- Time of India
Travelling to hill stations for fresh air? Toxic Himalayan clouds can damage lungs, kidneys and liver or give cancer
In the pristine altitudes of the Himalayas and the lush folds of the Western Ghats, clouds were once considered nature's purest gift, and symbols of untouched serenity and sources of sacred rain. However, this long-held belief is now under threat, as per the reports. A new scientific study, as reported in PIB , has revealed that these clouds are quietly carrying something far more sinister. It reported that the clouds are responsible for ferrying toxic heavy metals silently from polluted lowlands to some of the highest, most fragile ecosystems. These findings shatter the myth of 'clean' mountain rain, and also ring alarm bells for human health, which can lead to potential risks ranging from development disorders to cancer. Researchers from the Atmospheric Sciences Division of the Bose Institute, an autonomous body under the Department of Science and Technology (DST), have found that clouds drifting over the Eastern Himalayas and the Western Ghats are now acting as transport vehicles for toxic heavy metals, lifted from the polluted lowlands. These non-precipitating clouds, sampled during the onset of the Indian monsoon, contain harmful metals like cadmium (Cd), copper (Cu), chromium (Cr), and zinc (Zn). Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Eating these 15 Foods Every Day Will Slowly Kill You Undo by Taboola by Taboola The study, titled "Source-specific multi-pathway human health risk assessment of metals present in clouds over Indian Subcontinent,warns of alarming public health consequences and environmental degradation in two of India's most ecologically sensitive regions. The presence of such metals not only shatters the myth of pure mountain rainwater but also raises red flags about long-term risks—especially those related to carcinogenic and non-carcinogenic diseases. Read more: 5 hill stations in India to experience scenic cable car rides The research, led by Dr. Sanat Kumar Das, Associate Professor at the Bose Institute, quantified the human health risks associated with these pollutants using detailed statistical modelling. The study found that clouds over the Eastern Himalayas were particularly toxic, with 1.5 times higher pollution levels than their southern counterparts. This elevated toxicity was attributed to a 40–60% increase in heavy metal loading, primarily from vehicular and industrial emissions in the foothill regions. Crucially, the study identifies inhalation as the most potent route of exposure, particularly in the Eastern Himalayas. The presence of dissolved chromium in clouds was linked to increased risks of carcinogenic diseases, while non-carcinogenic effects were attributed to metals like cadmium, copper, and zinc. Children, the study found, are especially vulnerable—30% more at risk than adults—due to their higher sensitivity to airborne pollutants. Health threats come not just from breathing in these toxic clouds, but also through dermal contact and ingestion, especially in high-altitude regions where cloud moisture is often harvested or consumed as water. Read more: Spotted: 10 best places to see leopards in India Though the findings are concerning, the study, published in Environmental Advances, does offer a sliver of relief. It notes that Indian clouds remain relatively less polluted when compared to nations like China, Italy, and the USA, placing India in a safer health zone, for now. Still, the warning is clear. What once floated above as a symbol of purity is now a vessel of pollutants. The clouds may look the same, but what they carry could be putting both human health and fragile ecosystems at serious risk.
Time of India
2 hours ago
- Time of India
Gujarat ranks 3rd in sickle cell disease
Ahmedabad: Data tabled in the Lok Sabha on Aug 1 indicated that Gujarat, with 28,178 identified sickle cell disease patients, has the third-largest patient base in the country. Odisha, with 96,484 cases, leads the table, and is followed by Madhya Pradesh with 30,762 cases, according to data shared by Union health minister J P Nadda in response to a question by Rajkumar Raot. What set Gujarat apart was that 90% of the cases (25,282) were recorded among the scheduled tribes (ST), including those in the particularly vulnerable tribal group (PVTG) category, which was the highest among Indian states and significantly higher compared to Odisha and Madhya Pradesh, according to the statistics up to the end of July 2025. You Can Also Check: Ahmedabad AQI | Weather in Ahmedabad | Bank Holidays in Ahmedabad | Public Holidays in Ahmedabad The answer indicated that a total of 77.34 lakh citizens were screened to identify those with the condition. Under the National Sickle Cell Anaemia Elimination Mission (NSCAEM), persons with the condition are provided counselling regarding lifestyle, pre-marriage and pre-natal decisions and nutritional supplements among others. "The condition is marked by abnormal haemoglobin that makes red blood cells rigid and take the shape of a sickle. They often block the blood flow, leading to anaemia," a public health expert said. "Gujarat has recently launched a drive to understand the genetic makeup of the tribal population," the expert added.
&w=3840&q=100)
Business Standard
3 hours ago
- Business Standard
Eris Lifesciences to target insulin, semaglutide mkt opportunities in FY26
Ahmedabad-based Eris Lifesciences is looking to target opportunities in the nearly ₹5,000-crore Indian insulin market after Danish drugmaker Novo Nordisk announced a withdrawal of its insulin products in April this year. For Q1FY26, Eris Lifesciences recorded a 40 per cent year-on-year (Y-o-Y) rise in consolidated profit after tax (PAT) to ₹125 crore. Revenue rose to ₹773 crore during the June quarter against ₹720 crore in the year-ago period. 'We expect that Novo's cartridge inventory in the market will run out by October. So this market opportunity is something that one can start monetising from the November-December time frame,' the company's executive director and chief executive officer (CEO) Krishnakumar Vaidyanathan told Business Standard. He added that the timing fits Eris' plans as its Bhopal unit's cartridge filling capability will start getting operational from January. Vial manufacturing has already been commissioned at the Bhopal unit, with the company creating a strategic stock of insulins. This comes at a time when Eris already is the largest domestic player in insulin. The company had last year acquired the India formulations business of Biocon Biologics last year, including established insulin brands Basalog and Insugen. 'Before the Biocon deal, we had a couple of homegrown insulin brands in the market, which did a combined ₹60 crore in revenue last year. Basalog and Insugen had combined revenues of ₹200 crore at the time of acquisition,' he said. He added that with this, the company's insulin franchise has become really large with a 10 per cent market share. Eris is also among the prominent drugmakers looking to roll out generic versions of blockbuster molecule semaglutide once its patent expires around March next year. Semaglutide is a GLP-1 (glucagon-like peptide 1) receptor agonist that is used as an active pharmaceutical ingredient in medications for obesity management and Type-II diabetes. According to Eris' investor presentation for the June quarter of the financial year 2025-26 (Q1FY26), the company is on track to be among the first launches in India in March 2026. The company has initiated validation of synthetic semaglutide cartridges at its European Union (EU)-approved AMD injectables site. 'We are also planning the validation of the recombinant semaglutide in our Bhopal plant later this year,' he added. As far as the go-to market is concerned, the company said it is already in a strong position because of its dominant position in insulins and prior presence in the GLP market with the launch of Liraglutide in September last year.
